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Nifedipine for tocolysis
The release of the new WHO 
recommendations (October, 2015)1 
for preterm birth interventions is 
welcome. With regard to the place 
of tocolysis, the guidelines present 
a balanced view of the current 
uncertainties and indicate a preference 
for nifedipine as the drug of choice 
when tocolysis is considered, while 
emphasising the need for further 
research. However, an important issue 
in the availability and prescription 
of nifedipine is not covered in the 
WHO recommendations:2 that of the 
appropriate formulation for use in 
this indication. Although the evidence 
on nifedipine for tocolysis relates to 
immediate-release formulations, in 
low-resource countries only sustained-
release formulations, indicated for 
hypertension, are typically available. 
Thus clinicians may all too easily 
find themselves using the wrong 
formulation for tocolysis. 
There is no evidence to suggest 
that sustained-release nifedipine 
might have efficacy for tocolysis 
and there is notable  potential for 
harm: normotensive patients who 
are exposed to 30 mg of a sustained-
release formulation could become 
hypotensive over several hours. The 
immediate release formulation is 
appropriately specified in the WHO 
Model List of Essential Medicines3 
but making this available in clinical 
settings globally may be problematic. 
It does not have other therapeutic uses 
and might be approaching the status 
of an orphan drug. 
Should research confirm the 
usefulness of nifedipine as part of the 
package of interventions to improve 
the outcomes of preterm birth in 
low-resource settings, close attention 
will be required to drug procurement, 
supply-chain logistics, and methods 
to make the formulations clearly 
distinguishable at the point of care.
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